You are here: Industry Insights > Arcus

News List

Arcus CMO moving to Gilead to head clinical oncology research firstwordpharma
July 20, 2021
Arcus Biosciences disclosed in a US Securities and Exchange Commission filing Monday that chief medical officer Bill Grossman will transition out of his role at the company to take up the post of senior vice president of oncology clinical research.
Arcus says early data for anti-TIGIT domvanalimab combos look good, but mum on details firstwordpharma
June 24, 2021
Arcus Biosciences on Wednesday said a Phase II study testing combinations of its anti-TIGIT monoclonal antibody domvanalimab (AB154), which is partnered with Gilead Sciences, showed "encouraging" results when given as first-line treatment .
Gilead and Arcus Ink $2B Cancer Partnership contractpharma
June 01, 2020
To co-develop and co-commercialize next-generation cancer immunotherapies.
Arcus collaborates with Genentech for two randomised clinical studies of AB928 pharmaceutical-business-review
December 25, 2019
Arcus Biosciences announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC)
Gilead, Precision to co-develop hepatitis B therapies pharmatimes
September 18, 2018
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
Arcus adds WuXi Biologics-developed PD-1 drug under $816M deal fiercebiotech
August 21, 2017
In a potential $816 million deal, Arcus Biosciences gets exclusive rights to a PD-1 drug by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.